Neither albiglutide nor exenatide therapy resulted in significant ... and head-to-head versus glargine and liraglutide. One study will also evaluate albiglutide versus sitagliptin in patients ...
The FDA is probably using the exenatide LAR preclinical data to help assess whether the observations for liraglutide are a class effect, and its stance on the issue will be clarified by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback